HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alissa Marhäll Selected Research

gedatolisib

10/2019Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9-16].
1/2017The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alissa Marhäll Research Topics

Disease

3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2019 - 01/2017
3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
10/2019 - 01/2017
2Neoplasms (Cancer)
10/2019 - 01/2017
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2017 - 01/2017
1Weight Loss (Weight Reduction)
01/2017

Drug/Important Bio-Agent (IBA)

2gedatolisibIBA
10/2019 - 01/2017
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2017 - 01/2017
1Phosphotransferases (Kinase)IBA
10/2017
1Pharmaceutical PreparationsIBA
10/2017
1dinaciclibIBA
10/2017